Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q4 Preview: How Will Bayer Survive Patent Cliff?

Executive Summary

Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of surviving the patent expiries on Xarelto and Eylea.

Advertisement

Related Content

Bayer Confident It Can Cope With Patent Cliff Pain
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel